News for Cellebrite DI Ltd. (CLBT)

Cellebrite DI Ltd. (CLBT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

On December 31, 2024, Greenhaven Road Investment Management, L.P. (Trades, Portfolio) executed a significant transaction involving Lifecore Biomedical Inc. The

Shares of Cellebrite DI Ltd (CLBT) fell 5.30% in mid-day trading on Feb 14. The stock reached an intraday low of $20.35, before recovering slightly to $20.55,

Cellebrite DI Ltd. (NASDAQ:CLBT) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsAndrew Kramer - IRTom Hogan - Interim...

The following slide deck was published by Cellebrite DI Ltd.

Cellebrite DI Ltd. (CLBT) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Cellebrite DI Ltd (CLBT), a leader in digital investigative solutions, announced its financial results for the fourth quarter and full year ending December 31,

Company delivers ”œRule of 50” Performance in 2024 with 25% ARR growth and 25% adjusted EBITDA margin Fourth-quarter 2024 revenue of $109.0 million grew 17%

On December 31, 2024, Pertento Partners LLP (Trades, Portfolio) made a strategic decision to reduce its holdings in CRA International Inc (NASDAQ: CRAI). The fi

On December 31, 2024, FMR LLC (Trades, Portfolio) made a significant move by acquiring an additional 5,004,587 shares of Cellebrite DI Ltd (CLBT). This transact

Cellebrite DI Ltd (CLBT), a leader in digital investigative solutions, announced on February 12, 2025, that its Cellebrite Government Cloud platform has achieve

On December 31, 2024, ASHFORD CAPITAL MANAGEMENT INC (Trades, Portfolio) made a strategic decision to reduce its holdings in Red Violet Inc (RDVT) by 102,336 sh

**media[453435]**

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT) (“Cellebrite,” the “Company” or “we”), a...

Cellebrite Announces "Redemption Fair Market Value" in Connection with Redemption of All Outstanding Warrants

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT) (“Cellebrite,” the “Company” or “we”), a...

Cellebrite announces warrant redemption at $0.10 each

Cathie Wood has four decades of investment experience in the finance industry. Her focus as a portfolio manager is solely on publicly traded companies with

Cathie Wood Market Prediction According to the latest research report from Ark Investment Management Tesla stock is expected to trade at $4,600 in 2026. This is approximately seven times the price at which the stock of Elon Musk's company is currently trading.[1] Three years ago, ARK's forecast for EV sales in 2022 looked ridiculous at